Trials / Completed
CompletedNCT02257697
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Refractory Nephrotic Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 239 (actual)
- Sponsor
- Asahi Kasei Therapeutics Corporation · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mizoribine (MZR) | |
| DRUG | Cyclophosphamide (CTX) |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
- First posted
- 2014-10-06
- Last updated
- 2019-01-17
Locations
28 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02257697. Inclusion in this directory is not an endorsement.